Expert Discusses the Evolving Field of Gynecologic Cancers

Video

The field of ovarian cancer is changing rapidly, and moving toward an era of precision medicine.

It’s an exciting time for gynecologic malignancies, as treatment options continue to be explored, said Maurie Markman, M.D., resident of Medicine and Science, Cancer Treatment Centers of America.

Three PARP inhibitors are now approved for the treatment of ovarian cancer — Zejula (niraparib), Lynparza (olaparib) and Rubraca (rucaparib) – in the maintenance setting. Now, checkpoint inhibitors, a type of immunotherapy agent, are the next to be explored, according to Markman. An increase in molecular testing will continue to move the field into an era of precision medicine, where each patient will have a specific treatment plan that is tailored to their disease.

Related Videos
Jessica McDade, B.S.N., RN, OCN, in an interview with CURE
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey. If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key. “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained. READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE
Related Content
image of "hope" in a pair of hands.

Shining Through Cancer and Fear

April 7th 2024
Article

Even after surgery and chemotherapy, I make sure to shine through cancer and any fear that stares at me.

Read More

cancer horizons logo: a white microphone on a navy blue background

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

March 11th 2024
Podcast

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

Listen

Illustration of a woman with short gray hair, thing rectangular glasses and pink lipstick.

A Strange New World of Cancer Research Has a Cost

March 19th 2024
Article

My genetic testing covered 648 gene variants. Of course, researchers only know the significance of a fraction of those variants.

Read More

Shannon Miller smiling at a podium while delivering the keynote address at the 2023 Extraordinary Healer event | Image credit: © ATA-GIRL PHOTOGRAPHY

Olympian Shares Her Cancer Experience: ‘Give Yourself Grace’

May 4th 2023
Podcast

Olympic gymnast, Shannon Miller, sat down with CURE® to discuss her experience with a rare type of ovarian cancer, and how her competitive mindset helped her through.

Listen

Experimental cancer vaccine vial for immunization against Cancer disease. Doctor with vial of the Cancer vaccine | Image credit: © angellodeco - © stock.adobe.com

Ovarian Cancer Vaccine Trial Gets FDA Clearance To Proceed

March 6th 2024
Article

The Food and Drug Administration green lit a first-in-human phase 1 clinical study of Innocell, a vaccine for the treatment of stage 3 and 4 ovarian cancer.

Read More

female doctor in white coat with clipboard talking to patient

Cancer the Second Time Around

February 20th 2024
Article

After my treatment ended for triple-negative breast cancer, I thought I was done with cancer — and then I was diagnosed with ovarian cancer.

Read More